If you want to understand what pregnancy does to the human body, you usually have to wait. Researchers spend years finding participants, tracking their clinical visits, and hoping the manual data paints a clear picture. That waiting game changed on February 27, 2025, when Oura and the Scripps Research Digital Trials Center launched a retrospective study aiming to analyze 10,000 pregnancies using data that has already been recorded.
The Finnish tech company is taking a radically different approach to maternal science. Instead of recruiting newly pregnant people and tracking them for months, they are simply asking their existing users for permission to look at the past.
A Clinical Trial Built Entirely Backward
Traditional research crawls because the recruitment and observation phases are incredibly slow. Most studies struggle to keep pace with the real-world experiences of the people they are trying to help. This new joint effort completely flips that standard model on its head.
The researchers are starting with the data and working backward. Instead of enrolling individuals and watching things unfold over forty weeks, Oura is identifying members who have already gone through pregnancy and reaching out for their consent. Users simply log into the MyDataHelps platform through a card in the app, answer a few basic questions, and share their outcomes.
The total time commitment for a user is less than half an hour. Because the company has sold over 5.5 million rings since its founding, there are thousands of biometric timelines already recorded and sitting on servers.
| Research Feature | Traditional Medical Study | Oura Retrospective Study |
|---|---|---|
| Participant Recruitment | Takes months to years | Immediate opt-in from existing user base |
| Data Collection Method | Manual tracking and clinic visits | Passive 24/7 biometric tracking |
| Study Timeline | Several years from start to finish | Potentially completed in a few months |
| Available Sample Size | Usually small and localized | Tens of thousands across multiple demographics |
All the relevant physical changes are already mapped out in the background. Continuous metrics like sleep disturbances, heart rate variability, baseline temperature shifts, and stress patterns are ready to be analyzed immediately.
Spotting Complications Before They Happen
The stakes for this data analysis are exceptionally high. Oura and Scripps want to pinpoint early signs of conditions like preeclampsia, which remains one of the top causes of maternal and fetal death. The Centers for Disease Control estimates that preeclampsia contributes to over 70,000 maternal deaths and 500,000 fetal deaths globally every single year.
In the United States, the maternal mortality rate is stubbornly high compared to other developed nations. The outcomes are even worse for Black women, who face a 60 percent higher rate of preeclampsia compared to white women. Researchers are scrambling for new support mechanisms as federal funding for maternal health from organizations like the NIH faces recent cuts.
This initiative goes far beyond generic step-counting. The goal is to make sense of subtle physiological changes that a standard clinical study could easily miss between scattered doctor appointments. Early internal research from Oura’s data science team already shows clear trajectories, such as an average resting heart rate increase of 10 beats per minute by week 32 of pregnancy.
Hardware Upgrades Meeting Clinical Needs
Pulling off a study of this scale requires hardware that actually stays on the user’s finger during intense physical changes. Swelling is a notoriously common symptom during the second and third trimesters, which has historically made ring-based wearables difficult to wear long-term.
The release of the Oura Ring 4 in October 2024 aimed to solve this exact physical barrier. The company completely redesigned the internal architecture, moving to a fully titanium inner and outer shell while recessing the sensors so they no longer protrude into the skin.
More importantly, the new device relies on Smart Sensing technology with 18 distinct signal paths. This allows the ring to adapt to changing finger shapes, varying skin tones, and minor shifting without losing connection to the user’s pulse.
- The ring offers expanded sizes ranging from 4 up to 15, accommodating severe hand swelling.
- The recessed sensors prevent the deep skin indentations that caused users to abandon older models.
- Continuous temperature monitoring can detect physiological peaks of just +0.3 degrees Celsius.
- The battery holds enough charge to prevent data gaps during hospital stays or labor.
By keeping the device comfortable enough to wear 24/7, researchers get an uninterrupted look at the body’s baseline metrics right up until the moment of delivery.
“Women are traditionally under-researched and under-supported. Most wearables are oriented around men. This ring could be the doctor you never had – the one who knows you and has all the time in the world.” — Tom Hale, CEO of Oura
The 300-Dollar Elephant in the Room
There is no ignoring the obvious financial barrier to this kind of data collection. Oura rings are a premium product. They start at $299 for the base model, and the mandatory data subscription costs another $5.99 a month, or roughly $70 a year.
Dr. Robin Wallace from Planned Parenthood has publicly welcomed Oura’s research initiative but immediately raised concerns about the cost. She noted that new technology does not always guarantee equitable access to better healthcare. If the only people contributing to this 10,000-person study are those with disposable income, the resulting health insights may skew toward a specific, wealthier demographic.
Industry experts think the payment model will eventually shift to fix this gap. Christina Farr, health-tech journalist and managing director at Manatt, suggested that these devices could eventually be covered by insurance policies, similar to how breast pumps or Lamaze classes are subsidized today. Oura is already positioning itself for this future, securing HSA and FSA eligibility for ring purchases in the United States.
Data Privacy in a Highly Sensitive Era
Gathering detailed reproductive data from American women requires a level of trust that tech companies have struggled to maintain. The overturning of Roe v. Wade in 2022 sparked severe concerns about how apps handle menstrual and gestation timelines.
Oura operates under strict European data laws because it is headquartered in Finland, making it fully GDPR-compliant. CEO Tom Hale drew a hard line regarding the brand’s commitment to reproductive privacy, explicitly stating the company will oppose requests to provide authorities with user data for surveillance or prosecution.
This strict security framework is essential for rethinking privacy in the wearable space, especially when tracking conditions as sensitive as miscarriages or late-term complications.
- Participants must explicitly opt into the Scripps study via the MyDataHelps platform.
- Users have the option to link their broader medical records, but it is not mandatory.
- Data sets shared with clinical researchers are stripped of direct personal identifiers.
The company’s prior integration with Natural Cycles, the first FDA-cleared birth control app, proved that their temperature sensors met the strict clinical standards required for reproductive health. Now, they are trying to prove they can handle the diagnostic side of things just as responsibly.
Why Big Tech is Turning to Women’s Health
The move into maternal research is not just a philanthropic exercise. The broader shift toward female-focused health tools represents a major financial opportunity. The global FemTech market was estimated at $39.29 Billion in 2024 and is projected to reach over $97 billion by 2030.
Oura recognized this demographic shift early on. Three years ago, roughly 70 percent of their user base was male. By early 2026, internal projections suggest that ratio will entirely flip, with women making up nearly 70 percent of all active wearers.
The launch of a dedicated Pregnancy Insights feature in March 2024 was the first major step in capturing this audience. It allowed users to track their gestational age alongside the weekly physiological changes happening in their bodies.
For decades, researchers have been looking for the earliest possible signals that something might go wrong for expecting mothers. By tapping into the millions of data points already sitting on our fingers, the medical community might finally get the answers they have been waiting for. The success of this massive retrospective trial could permanently alter the pace of #MaternalHealth research, proving that consumer #WearableTech is fully capable of doing the heavy lifting for clinical science.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Pregnancy-related complications require professional clinical diagnosis and care. Always consult a qualified obstetrician or healthcare provider regarding any unusual symptoms or health concerns during pregnancy.
